Immunology-oncology ELISA Kits Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Immune-Checkpoint Inhibitor Development Broadens the Assay Target Universe

The immunology-oncology ELISA kits market is supported by an immunotherapy pipeline extending beyond PD-1 and CTLA-4 to include LAG-3, TIM-3, and TIGIT. These targets require dedicated soluble protein measurement methods for pharmacodynamic monitoring and translational biomarker research. A 2025 metastatic melanoma study evaluated 7 soluble immune-checkpoint proteins, including sPD-1, sPD-L1, sLAG-3, and sCTLA-4, in 110 patients using commercial ELISA kits, highlighting the value of multi-marker liquid-biopsy panels.^{[2]A. Azzariti et al., “Developing a Risk Score Using Liquid Biopsy Biomarkers for Selecting Immunotherapy Responders and Stratifying Disease Progression Risk in Metastatic Melanoma Patients,” Journal of Experimental & Clinical Cancer Research, link.springer.com.} Emerging targets can create separate assay categories before related therapies receive regulatory approval, supporting recurring kit demand across clinical research programs.

Companion-Diagnostic and Biomarker Validation Programs Drive Clinical-Grade Kit Adoption

Companion-diagnostic programs require quantitative evidence, increasing the use of validated assay platforms during biomarker development. ELISA kits are commonly used for early biomarker validation before tissue-based diagnostic workflows are finalized. In March 2026, Agilent received its 8th FDA companion diagnostic indication for PD-L1 IHC 22C3 pharmDx for esophageal or gastroesophageal junction carcinoma patients eligible for pembrolizumab.^{[3]Unraveling Tumor Cell-Tumor Microenvironment Crosstalk Through Antibody Array Technologies,” International Journal of Oncology, doi.org.} This trend supported demand for clinical-grade ELISA kits with clear performance specifications, reproducible results, and stable supply across study sites.

Quantitative Tumor-Microenvironment Profiling Elevates Assay Sensitivity Requirements

Tumor-microenvironment research is shifting toward repeated profiling of cytokines and checkpoint proteins, requiring the detection of low-abundance analytes in complex samples. A 2025 review found that antibody-array studies could identify altered checkpoint signaling below 10 pg/mL. Chemiluminescent and fluorescent ELISA formats provide the required analytical sensitivity, driving demand for platforms with wider dynamic ranges. The 4.76% CAGR forecast for chemiluminescent ELISA reflected this shift toward higher-performance assays and reduced repeat testing.

Asia-Pacific Clinical-Trial Expansion Creates Sustained Institutional Procurement

Asia-Pacific is gaining importance in the immunology-oncology ELISA kits market as oncology trial activity has increased across China, India, Japan, and South Korea. China’s tier-one cancer centers expanded biomarker research and local manufacturing capacity, while Japan’s accelerated review pathways and India’s growing contract research organization base supported assay demand. In May 2026, AstraZeneca and Roche Diagnostics Asia Pacific announced a 3-year memorandum of understanding to advance digital and companion-diagnostic programs across Asia-Pacific, prioritizing validated PD-L1, HER2, and antibody-drug conjugate biomarker assays. This activity supported demand for research and clinical-grade assays, particularly among laboratories requiring regulatory documentation, familiar ELISA workflows, and reusable standard curves.

Absence of Standardized PD-1/PD-L1 Cutoffs Restricts Clinical Decision-Making

The lack of standardized reference ranges for soluble PD-1 and PD-L1 limited the clinical utility of accurate ELISA results. A 2025 study in advanced non-small cell lung cancer reported a hazard ratio of 2.10 for reduced overall survival associated with pretreatment sPD-L1 among pembrolizumab-treated patients. However, the absence of common clinical cutoffs prevented consistent interpretation across institutions and kept much of the testing in research-use-only settings. This gap constrained IVD-grade product adoption, despite their higher revenue per test than research-use alternatives. Interlaboratory studies and alignment on sample handling, calibration, and reporting were required to ensure comparable results. National metrology organizations could support ISO-aligned harmonization, but no consensus had been reached for soluble checkpoint analytes. Consequently, the immunology-oncology ELISA kits market grew through research use, while clinical adoption developed more slowly. Clear clinical thresholds would make routine testing demand more predictable and increase the value of validated kits for diagnostic centers and hospitals.

Multiplex and Molecular Platforms Compress ELISA’s Share in High-Resource Settings

Multiplex, flow-based, and molecular platforms compete with ELISA in well-funded reference laboratories that require broad biomarker panels from a single sample. The 2025 AACR Annual Meeting included a RADIOHEAD cohort study using nELISA plasma profiling in checkpoint inhibitor patients, described as the largest plasma proteomics analysis of this patient group to date. These platforms can measure hundreds of biomarkers from one plasma aliquot, supporting discovery-stage research, particularly in North American and European laboratories with larger budgets. However, multiplex discovery studies can lead to single-analyte ELISA testing for focused validation and clinical translation, while ELISA remains relevant for targeted, familiar, and reproducible testing; cold-chain requirements and shelf-life limitations also restrict access in rural Asia-Pacific, South America, and parts of the Middle East and Africa.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Immunology-oncology ELISA Kits Market Segment Analysis

Direct ELISA kits held 41.45% of global revenue in 2025. Their single-antibody format reduces procedural steps and limits cross-reactivity risks in serum and plasma workflows. This simplicity supports high-volume hospital laboratories that rely on standardized procedures and consistent sample handling. Indirect ELISA kits are forecast to grow at a CAGR of 4.33% through 2031, supported by signal amplification for low-abundance targets, including sPD-L1, sLAG-3, and sTIM-3.

The Others category includes sandwich and competitive ELISA formats for cytokine quantification and competitive inhibition assays. These formats support applications where analyte concentrations exceed standard calibration limits. In 2025, a study used Proteintech Human PD-1 and PD-L1 sandwich ELISA kits in 55 patients with advanced non-small cell lung cancer receiving pembrolizumab. The kits demonstrated intra-assay coefficients of variation below 7.8% and detection ranges of 0.156-10 ng/mL, reflecting the precision required in clinical research.

Colorimetric ELISA held 36.76% of detection-technology revenue in 2025. The format is compatible with standard 96-well plate readers and familiar laboratory procedures. Its lower cost supports high-throughput screening and laboratories with varying resource levels, particularly in the Asia-Pacific and South America. Chemiluminescent ELISA is forecast to grow at a CAGR of 4.76% through 2031, driven by demand for low-concentration checkpoint protein measurement and immunotherapy monitoring.

Abcam launched SimpleStep Ignite ELISA in April 2026 as a chemiluminescent platform that delivers results in 55 minutes. The company stated that the platform provides 50-fold greater sensitivity and up to a 35-fold wider dynamic range than traditional colorimetric ELISAs. Stricter documentation and performance requirements under the In Vitro Diagnostic Regulation are supporting upgrades to higher-specification systems, although cost and installed equipment continue to sustain demand for colorimetric ELISA.

Disease diagnosis accounted for 52.67% of the immunology-oncology ELISA kits market size in 2025. Hospital oncology departments use ELISA panels to quantify soluble biomarkers in newly diagnosed cancer patients, including in pre-immunotherapy workups in some settings. Treatment-response monitoring generates recurring demand, while clinical research uses research-use-only kits. Drug discovery and development is forecast to grow at a CAGR of 5.56% through 2031, driven by early screening, pharmacokinetic bridging assays, and immunogenicity assessments.

Bio-Rad expanded its anti-idiotypic antibody pairs for pharmacokinetic bridging ELISAs in April 2026. The expansion covered tremelimumab, an anti-CTLA-4 therapy; elotuzumab, an anti-SLAMF7 therapy; and isatuximab, an anti-CD38 therapy. The company also added reagents for four other immunotherapy biologics and an anti-Fc mutation antibody panel for YTE-modified IgG1 therapeutics. These reagents support free-drug measurement and standardized pharmacokinetic monitoring across drug development studies.

Blood held 44.34% of sample-type revenue in 2025. Blood-based testing supports serial collection without additional tissue-sampling burden on patients. Laboratories use serum to measure soluble checkpoint proteins and EDTA plasma to assess circulating cytokine profiles. Tissue is forecast to grow at a CAGR of 5.98% through 2031, driven by tumor-microenvironment profiling using tumor lysates, cell-culture supernatants, and tissue homogenates.

A 2025 Communications Biology study used Invitrogen ELISA kits to measure IFN-γ and Granzyme B in breast cancer patient-derived scaffold co-cultures containing autologous T cells. The study demonstrated the value of protein-level measurements in reconstructed ex vivo tumor-microenvironment models. Tissue samples present higher matrix-interference risks and require broader dynamic ranges and validated dilution linearity. Blood remains important for repeat monitoring, while tissue supports analysis of local immune activity in the tumor environment.

Hospitals accounted for 48.12% of end-user revenue in 2025, supported by high testing volumes and procurement contracts across oncology departments, biobanks, and laboratory services. Pharmaceutical and biotechnology companies purchase kits for preclinical biomarker research and clinical studies, while academic and government research institutes support demand through investigator-led trials. Diagnostic centers are forecast to grow at a CAGR of 6.34% through 2031 as repeat immunotherapy monitoring becomes more decentralized.

Revvity’s EUROIMMUN unveiled the IDS i20 in May 2025 as a CE-marked and FDA-listed automated chemiluminescence immunoassay platform. The system runs 20 analytes across six diagnostic specialties simultaneously. Diagnostic centers can reduce cost per test through consolidated and automated workflows. Hospital laboratories may adopt these systems more gradually because of broader and less predictable testing requirements, while pharmaceutical companies and research institutes continue to require specialized assay support.

Geography Analysis

North America Immunology-oncology ELISA Kits Market

North America held a 40.35% share of the immunology-oncology ELISA kits market in 2025. The region benefits from extensive oncology trials, pharmaceutical research expenditure, and companion diagnostic activity, led by the United States and supported by Canadian academic cancer centers and biobank programs. FDA requirements for validated data in investigational new drug-enabling studies support demand for high-specification kits and create entry barriers for suppliers with consistent lot-to-lot performance. In April 2026, Labcorp launched an FDA-approved companion diagnostic for ovarian cancer to identify patients eligible for KEYTRUDA, marking the first immuno-oncology approval for this indication.

Europe Immunology-oncology ELISA Kits Market

Europe remains a substantial and stable market for immunology-oncology ELISA kits, with Germany, the United Kingdom, and France accounting for a significant share of regional procurement. The In Vitro Diagnostic Regulation increases performance and documentation requirements for IVD products through 2025 and 2026, encouraging laboratories to transition to CE-marked alternatives. This trend consolidates procurement among suppliers with strong compliance documentation and consistent performance data. Italy, Spain, Nordic countries, and Eastern European countries support demand through oncology biomarker studies, expanding immunoassay infrastructure, and ISO 15189-accredited laboratory quality systems.

APAC, MEA and South America Immunology-oncology ELISA Kits Market

Asia-Pacific is forecast to grow at a CAGR of 6.25% through 2031, driven by the expansion of China’s tier-one cancer centers and growing regional manufacturing capacity. Japan’s PMDA accelerated review pathways, and India’s CDSCO alignment with the FDA and EMA companion diagnostic validation practices support biomarker-led therapy programs. Demand in the Middle East and Africa is concentrated in Gulf Cooperation Council tertiary hospitals and selected South African oncology centers, while Brazil and Argentina lead the South American market. Cold-chain constraints, institutional funding cycles, and foreign-exchange volatility may moderate growth outside major regional centers.